Figure 1.
Exposure to treatment with interferon β-1a SC thrice weekly.
Numbers of patients treated with Rebif recorded within the MSBase registry (n = 4678) and stratified by time on treatment are shown. Red bar in year 1 indicates the proportion of patients in whom dose escalation was a planned procedure. TIW, three times weekly.
Figure 2.
Likelihood of discontinuation by exposure to treatment.
Overall proportion of treatment discontinuations in patients treated with either Rebif dosage is shown (left). Discontinuation rates by the recorded reasons are shown. Hazard ratio (HR) is given where significantly different from 1, dashed lines represent 95% confidence intervals. Planned dose escalations within the first year of treatment are not included. HR, hazard ratio; TIW, three times weekly.
Table 1.
Discontinuation events.
Table 2.
Baseline demographic and clinical data in patients unmatched and matched by the propensity score.
Figure 3.
Kaplan-Meier plots for the proportion of patients free from clinical relapses.
No statistically significant differences between the treatment dosages were observed. MRI, magnetic resonance imaging; TIW, three times weekly.
Table 3.
Clinical outcomes at two years of treatment in the patient groups matched on propensity scores.
Table 4.
Baseline demographic, clinical and MRI data in the sub-group with available MRI, unmatched and matched by the propensity score.